Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Carcinoma

Carcinoma, Lobular

Carcinoma, Ductal, Breast

Carcinoma, Ductal

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Breast Diseases

Skin Diseases

Adenocarcinoma

Radiomic, pathomic, and clinical markers

William T. Tran, MRT(T), PhD

Kasia Jerzak, M.Sc., MD

Fang-I Lu, MD, FRCPC

This study examines retrospective clinical data on patients diagnosed with breast cancer and monitor their response to neoadjuvant chemotherapy, incidence of locoregional recurrence, distant metastasis, and disease-free survival. The hypothesis of this study is that breast cancer patients who achieve a pathological complete response (pCR) to neoadjuvant chemotherapy demonstrate distinct clinicopathomic biomarker signatures.

The specific aims of the study are to (1) to identify clinicopathomic biomarkers from pre-treatment core biopsies that are predictive of response to neoadjuvant chemotherapy, (2) determine patterns of metastasis from primary breast cancer to other distant sites, (3) determine the rates of local recurrence in breast cancer patients, and (4) to determine if there are significant radiomic, pathomic, and clinical markers for recurrence and distant metastasis.

Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer

All data will be anonymized. Digital pathology images and anonymized clinical data will be deposited into the National Cancer Institute (NCI) data sharing repository, including The Cancer Imaging Archive (TCIA). Digital pathology images will also be annotated to facilitate analysis for other investigators. Computational methods, source-codes and instructions will be deposited to the open-source coding repository, GitHub (www.github.com).

Evaluating the degree of absence of residual cancer cells

Evaluating the time until a recurrence event has occurred in the breast

Sunnybrook Health Sciences Centre

Radiation Therapist Clinician Scientist

Symptoms and General Pathology

Recurrence

Carcinoma, Squamous Cell

Squamous Cell Carcinoma of Head and Neck

Head and Neck Neoplasms

Neoplasms, Squamous Cell

Disease Attributes

William Tran, MRT(T), PhD

Here, the investigators will develop a clinicopathomic assay from biomarkers obtained from digital pathologies of resected whole-mount oral cavity and oropharyngeal squamous cell carcinoma (OCSCC and OPSCC) specimens with the goal of administering personalized novel image-guided therapies immediately after primary surgical management in OCSCC and OPSCC patients. The primary aim is to determine the association between clinicopathomic biomarkers and LRR. The secondary aim is to develop a clinicopathomic risk score (assay) such that a decision-support tool can be used by physicians for measuring the benefit of additional therapies (i.e. conventional chemotherapy +/- radiation or administering dose-escalated chemoradiation) in the adjuvant setting to reduce LRR rates.

The proposed study is significant for developing personalized treatments. The proposed research will yield high rewards to patients by providing additional information to clinicians for better prognostication and potentially adapting adjuvant treatments to improve the survival of patients with OCSCC or OPSCC.

Analysis of Patterns of Recurrence in Head and Neck Cancer Using Clinicopathomic Markers

Evaluating the time until a recurrence event has occurred in the oral cavity or oropharyngeal region

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer	NCT04021069	Breast Cancer Invasive Ductal... Invasive Lobula...	Radiomic, patho...	18 Years -	Sunnybrook Health Sciences Centre
Analysis of Patterns of Recurrence in Head and Neck Cancer Using Clinicopathomic Markers	NCT04086849	Head and Neck N... Squamous Cell C...	Radiomic, patho...	18 Years -	Sunnybrook Health Sciences Centre
Analysis of Patterns of Recurrence in Head and Neck Cancer Using Clinicopathomic Markers	NCT04086849	Head and Neck N... Squamous Cell C...	Radiomic, patho...	18 Years -	Sunnybrook Health Sciences Centre

Spots Global Cancer Trial Database for radiomic, pathomic, and clinical markers